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AbstrACt
background Prostate cancer incidence varies 
internationally largely attributable to differences in 
prostate-specific antigen (PSA) use. The aim of this study 
was to provide the most recent detailed international 
epidemiological comparison of prostate cancer incidence 
and mortality in six north-eastern European countries 
(Belarus, Estonia, Latvia, Lithuania, the Russian Federation 
and Ukraine).
Methods The number of incident prostate cancer cases 
was obtained from the countries national cancer registries. 
Prostate cancer mortality and corresponding population 
data were extracted from the WHO Mortality Database. 
Age-specific and age-standardised incidence and mortality 
rates were calculated (European Standard). The joinpoint 
regression model was used to provide an average annual 
percentage change and to detect points in time where 
significant changes in trends occurred. The observation 
period was between 13 (Ukraine) and 48 (Estonia) years 
regarding incidence and around 30 years regarding 
mortality.
results The comparison of prostate cancer incidence in 
six European countries showed almost sixfold differences 
in the age-adjusted rates in most recent years with 
highest incidence rates in Lithuania and Estonia. Through 
the observation period, overall a continuous rise was 
seen in incidence in all countries and a continuous rise in 
mortality, with a stabilisation in Estonia and a decrease 
in Lithuania in recent years. Data limitations included a 
descriptive design using ecological data.
Conclusions A widespread use of PSA testing seems to 
be responsible for the changes in the epidemiology of the 
disease in north-eastern European countries. Substantial 
variation in the incidence of prostate cancer in the Baltic 
states suggests the possibility that PSA performance and 
utilisation spread have had a major influence on observed 
incidence trends, with a lack of effect on prostate cancer 
mortality.
IntroduCtIon
Prostate cancer was estimated to be the third 
most common cancer site in Europe in 2018 
with 450 000 cases being diagnosed and it 
being ranked as the fifth leading cause of 
cancer death with 107 000 deaths.1 Although 
the aetiology of prostate cancer remains 
unknown, there are established risk factors 
for developing prostate cancer, including 
older age, a black racial background and a 
family history of the disease.2 Prevalence of 
other known risk factors, such as saturated 
fat intake, sedentary lifestyle and obesity, 
varies geographically worldwide and plays a 
role in prostate cancer incidence.2 Trends in 
prostate cancer incidence have been strongly 
influenced by prostate-specific antigen (PSA) 
testing3 and widespread use of the PSA test is 
held responsible for the large rise in prostate 
cancer incidence in most European countries 
and worldwide.4 5 Incidence and mortality 
trends of prostate cancer have been analysed 
in several large-scale studies across Europe 
and worldwide.6–9 Incidence increase was 
mostly accompanied by a mortality decrease 
in western and northern European countries, 
while in the Baltic states, Belarus, the Russian 
Federation and Ukraine a steady mortality 
increase was found.7 10
The aim of this study was to provide the most 
recent detailed international epidemiological 
comparison of prostate cancer incidence and 
mortality in six north-eastern European coun-
tries (Belarus, Estonia, Latvia, Lithuania, the 
Russian Federation and Ukraine).
strengths and limitations of this study
 ► This is a descriptive international study using na-
tional ecological data.
 ► This study provides a detailed updated international 
epidemiological comparison of age-specific pros-
tate cancer incidence and mortality trends in six 
north-eastern European countries.
 ► Lack of information on prostate-specific antigen 
(PSA) testing by age and calendar year for the study 
countries limits the opportunity for targeted analysis 
of association for PSA use with incidence data.
 ► Differences in data quality between countries and 
over time may have influenced the results.
 ► An additional study limitation was the lack of data 
on tumour stage.
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Table 1 Study group characteristics and period range of incidence and mortality data obtained, and availability of incidence 
data in Cancer Incidence in Five Continents (CI5)
Country
2011–2015 Available for analysis
Included in 
CI5
DCO 
(%)
MV 
(%)
Annual male 
population 
(millions)
Average 
annual 
number of 
incident 
cases
Average 
annual 
number of 
deaths Incidence Mortality
Belarus 4.4 3621 803 1990–2016 1985–2003 and 2008–
2015
1988–2012 – 98.3
Estonia 0.6 1130 260 1968–2015 1985–2015 1968–2012 – 95.6
Latvia 0.9 1118 387 1980–2016 1985–2015 1983–2012 6.0 85.3
Lithuania 1.4 3180 537 1978–2016 1985–2016 1988–2012 1.7 94.5
Russian 
Federation
66.6 33 039 11 172 1993–2015* 1985–2015 1993–2012 0.1 79.0
Ukraine 20.5 7753 3481 2000–2012† 1985–2012 and 2014–
2015
2003–2012 0.5 75.8
*Only from Saint Petersburg, 1998–2012—four cancer registries.
†For later period, not available due to lack of information from occupied regions of Ukraine.
DCO, death certificate only cases; MV, microscopically verified.
Methods
The number of incident prostate cancer cases (Interna-
tional Classification of Diseases (ICD)-9 185 and ICD-10 
C61) by 5-year age groups was obtained from the coun-
tries’ national cancer registries from the start of data 
collection to the latest available. The period range of the 
obtained data is presented in table 1. The breadth of inci-
dence data received from the cancer registries was larger 
than that included in volumes of ‘Cancer Incidence in 
Five Continents’ (CI5),11 which are submitted to system-
atic quality control (table 1). Belarus, Estonia, Latvia and 
Lithuania have a long history of cancer registration, and 
data from those registries have been published in CI5 
for decades. Cancer incidence data from Ukraine at the 
national level were published in volumes X–XI of the CI5 
covering the period of 2003–2012. Four cancer registries 
from the Russian Federation were included in the latest 
volume of CI5, whereas previous data were published only 
from St. Petersburg. For the current analysis, national 
data aggregated from all regional registries were used. 
Data from these sources were previously used to evaluate 
the national cervical and breast cancer burden.12
Prostate cancer mortality data were extracted from 
the WHO Mortality Database by 5-year age groups from 
1985 to the latest year available.13 Data suitable for the 
analysis of time trends until 2015 or 2016 were available 
for four countries (Estonia, Latvia, Lithuania and the 
Russian Federation), but for Belarus, an analysis of time 
trends was carried out only until 2003 due to data gap 
in the period 2004–2007. For Ukraine, the mortality data 
were available from the years 1998–2012, and then for the 
years 2014 and 2015. The observation period was between 
13 (Ukraine) and 48 (Estonia) years for incidence and 
around 30 years for mortality. Corresponding population 
data by age and calendar year were also extracted from 
the WHO Mortality Database.
Age-specific and age-standardised incidence and 
mortality rates were calculated. Age-standardised inci-
dence and mortality rates per 100 000 person-years were 
standardised to the European population (Standard of 
1976). Age-standardised rates were calculated for each 
calendar year for all ages combined, and age-specific 
rates for ages 50–74 and 75+ years. For comparison of 
mean incidence and mortality rates, years between 1995 
and 1999 were defined as the pre-PSA period, and years 
between 2011 and 2015 as the post-PSA period. The 
pre-PSA period was defined according to the information 
on PSA availability in countries under study. The period 
2011–2015 was defined as post-PSA under the assumption 
of widespread use of PSA tests.
Joinpoint regression was used to provide annual 
percentage changes (APC) and to detect points in time 
where statistically significant changes in the trends 
occurred. The average APC (AAPC) is a geometrically 
weighted average of APC values, with weights based on 
lengths of each segment during the whole observation 
period. In the absence of joinpoints, the APC’s and 
AAPC’s are equal. The joinpoint regression analysis iden-
tifies the best-fitting points (‘joinpoints’) where a signif-
icant change in the linear slope (on a log scale) of the 
trend is detected. The tests of significance use a Monte 
Carlo permutation method. Annual per cent changes 
were considered statistically significant if p<0.05. Join-
point analysis was performed for all ages combined and 
for the age groups 50–74 and 75+ years. A maximum 
number of three joinpoints were allowed for estimations. 
The minimum number of observations from a joinpoint 
to either end of the data was defined as three, and the 
H
ospital of Tam
pere. Protected by copyright.
 o
n
 O
ctober 29, 2019 at Tam
pere University and University
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031856 on 9 October 2019. Downloaded from 
3Patasius A, et al. BMJ Open 2019;9:e031856. doi:10.1136/bmjopen-2019-031856
Open access
minimum number of observations between two join-
points as two (excluding any joinpoint that falls on an 
observation). Joinpoint software V.4.3.1.0 was used.
Patient and public involvement
There was no direct patient involvement. Only aggre-
gated data were used.
results
Incidence
The comparison of prostate cancer incidence in six Euro-
pean countries showed almost a sixfold differences in 
the age-adjusted rates in the most recent years (table 2). 
Based on age-standardised rates in 2011–2015, the coun-
tries could be separated into two groups: high-incidence 
and low-incidence countries (ie, rates per 100 000 above 
and below 100 cases, respectively). High incidence was 
observed in the Baltic states and low incidence in Belarus, 
the Russian Federation and Ukraine. An incidence 
increase was seen in all countries over the entire study 
period, with the annual APC ranging between 3.4 in 
Ukraine and 7.4 in Lithuania. Joinpoint analysis showed 
a continuous increase in incidence in Ukraine (no join-
points) and generally increasing trends in Belarus, Latvia 
and the Russian Federation but with joinpoints suggesting 
different magnitudes of increase in different periods (see 
table 2 for joinpoints). Following a continuous rise in 
incidence and a marked increase, Lithuania and Estonia 
experienced decreases in incidence.
Prostate cancer incidence showed a general increase in 
countries in all age groups (figure 1). Among men aged 
50–74 years incidence peaks were observed in Estonia 
and Lithuania, followed by an incidence decrease in 
Estonia since 2011 and in Lithuania since 2007. Results of 
detailed joinpoint analysis by age group are presented in 
online supplementary table 1.
Age-specific incidence distributions in the period 1995–
1999 before implementation of PSA in clinical practice indi-
cated the highest incidence in all the countries in the 80–84 
years age group, with the highest age-standardised rate of 
753.0 cases per 100 000 applying to Estonia (figure 2). 
During the period 2011–2015, the peak incidence shifted 
to younger age groups (70–74 and 75–79 years), with the 
highest age-specific rate of 1261.0 cases per 100 000 in Lith-
uania applying to the 70–74 years age group.
Mortality
The differences in mortality rates among all countries 
were relatively small (table 2). As for incidence rates, 
higher mortality rates were observed in the Baltic states, 
while lower rates were observed in Belarus, the Russian 
Federation and Ukraine (ASR above and below 30 cases 
per 100 000, respectively). All countries experienced a 
general mortality increase throughout the observation 
period, but in the most recent years, mortality stabilisa-
tion is observed in Latvia and Estonia, and a mortality 
decrease in Lithuania. Mortality trends in age-specific 
groups paralleled changes in overall mortality (online 
supplementary table 1).
Age-specific mortality distributions were similar in both 
periods, with the highest mortality rates in the age group 
85+ years (figure 2). No mortality shift between age groups 
was observed. Mortality rates differed markedly between 
two country groups: in the Baltic states, mortality rates 
were almost three times higher in the period 1995–1999. 
In the period 2011–2015, observed mortality rates in the 
oldest age groups doubled; however, the relative difference 
between the Baltic states and the other countries remained 
the same.
dIsCussIon
When comparing trends in prostate cancer incidence 
and mortality across six north-eastern European coun-
tries, differences were observed between two groups of 
countries. In the Baltic states, prostate cancer incidence 
was higher than in Belarus, the Russian Federation and 
Ukraine. Throughout the study period, a general rise was 
seen in incidence in all countries and a general rise in 
mortality, with a stabilisation in Estonia and decrease in 
Lithuania in recent years.
Differences in risk factors for specific cancers between 
regions, in international cancer control plans and in 
cancer screening strategies may have contributed to inci-
dence and mortality differences between regions.14 The 
rising incidence may reflect the increased risk of disease 
or higher uptake of PSA tests.7 The incidence trends 
and patterns may be largely a function of the use of PSA 
testing.6 8 Healthcare expenditure availability of medical 
resources may also be an important contributor to the 
patterns of international variation in prostate cancer inci-
dence.15 Differences in data quality between countries 
and over time may have influenced the results.
Countries included in our study had different profiles 
of PSA testing uptake. In Lithuania, PSA became avail-
able in 2000, and in 2006, a nationwide PSA-based pros-
tate cancer early detection programme was started. Since 
the start of the programme in the period of 2006–2010, 
around 72%–78% of the total eligible male popula-
tion received at least one PSA test. No official prostate 
cancer screening programme has been introduced in 
Estonia, although in clinical practice, primary care physi-
cians routinely offer the test to middle-aged and elderly 
men, and patients themselves actively request the test.16 
According to a population-based health behaviour survey 
in 2016, the proportion of men who reported to have 
never had a PSA test was nearly 50% in the age group 
55–64 years, and nearly 60% in the age group 45–54 
years.17 In Latvia, PSA tests were not funded by the govern-
ment and the frequency testing was determined by the 
urologist.18 In 2015, it was recommended that PSA testing 
be used from the age of 50 years onwards. Some prostate 
cancer screening activity was observed in other countries: 
Belarus from 2011 to 2012 had a pilot screening project 
in three regions of the capital city for men aged 50–65 
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Figure 1 Trends in age-adjusted and age-specific prostate cancer incidence and mortality in six European countries.
years, with a PSA cut-off of 4 ng/mL.19 In the Russian 
Federation, PSA testing was introduced in the 1990s. 
Furthermore, PSA has been included in the national 
health check-up programme since 2013. This programme 
included other tests for other cancers and no formal 
and detailed information about the PSA cut-off value or 
settings for check-ups in this programme are available. In 
Ukraine, PSA check-ups for the population started quite 
late, compared with other countries. Formally, the PSA 
test was added to national guidelines for diagnostics of 
different locations and the state oncology programme of 
Ukraine, although no information regarding implemen-
tation and results of screening is available.
During the past 20 years, due to more extensive endo-
scopic benign prostate hyperplasia surgery, developing 
imaging techniques and PSA testing, higher prostate 
cancer rates have been observed in developed countries.5 
A rapid increase in prostate cancer incidence appears 
mostly to be associated with the widespread use of the 
PSA test since the middle of 1980s.3 5–7 PSA use in clin-
ical practice in north-eastern European countries began 
in the mid-to-late 1990s which reportedly reached almost 
70% of males in some populations.7 16 18 20 There were 
sporadic occurrences of prostate cancer screening in the 
study countries.19 In Lithuania, in 2006, a prostate cancer 
early detection programme was introduced as part of a 
nationwide opportunistic PSA test-based prostate cancer 
screening initiative. Incidence changes in Lithuania paral-
leled changes in prostate cancer incidence in the USA 
reported for the early 1990s.18 There was a rapid incidence 
peak after the start of the screening programme, followed 
by a decrease thereafter. It was caused by initial detection 
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Figure 2 Age-specific incidence and mortality in periods 1995–1999 and 2011–2015.
of a so-called ‘backlog’ of prevalent cancers that had accu-
mulated as a result of previous years’ incidence, described 
by Mettlin.21 It is notable that similar incidence changes 
have been observed in Estonia, where the PSA uptake 
is relatively high in the male population, according to a 
health behaviour study reported in 2016.17 The role of 
PSA-testing in incidence trends is further supported by 
the fact that the incidence increase in Estonia was shown 
to be limited to localised cancers.16
Besides the tangible benefits of PSA testing, which 
appears to be small based on recent mortality data, the 
test may also cause unwanted harms, such as overdiagnosis 
or detection of indolent tumours,22 and as a consequence 
of overdiagnosis, overtreatment23 and reduction in life 
quality.24 Although PSA screening may be beneficial in an 
organised setting,25 the net effect of a higher PSA uptake 
at a population level could be negative due to side effects.
For the most part, prostate cancer is a latent, slowly 
progressing disease. A long period of time might be 
necessary before the mortality declines at the popula-
tion level. Also, such a decline may occur in a different 
age group rather than the age at diagnosis.8 In our anal-
ysis, no mortality decrease was found in Lithuania in the 
age group 50–74 years and a slight mortality slope was 
observed in the age group 75+ years after 2006. This 
is consistent with the US data where a decrease in the 
mean age at diagnosis followed PSA use.23 The same 
effect is observed in our study. The highest age-specific 
incidence rates observed before implementation of 
PSA testing in clinical practice were seen in the 80–84 
years age group in all countries. However, in more 
recent years, peak incidence rates shifted to younger 
age groups (ie, 60–64 and 70–74 years). By comparison, 
peak mortality rates shifted to older age groups from 
80–84 to 85+ years after implementation of PSA testing 
in clinical practice. These changes could be a reflection 
of the PSA screening effect.
The Baltic states during the last decades have experienced 
a steep average incidence increase with a rather stable 
mortality,5 although mortality in our study in the Baltic 
countries has had a continuous growth, with stabilisation in 
Estonia and Latvia and a decrease in Lithuania since 2006 
by 1.4% annually. The year when decrease started, coinci-
dently, is the same as the start of the prostate cancer early 
detection programme in Lithuania. This could be misinter-
preted as a success of the early effect of this programme. 
However, according to the data from randomised 
controlled PSA screening trials, the first mortality reduc-
tion is observed at least 9 years after the beginning of the 
trial.26 The mortality decrease in Lithuania, starting in the 
same year the screening started, is, therefore, unlikely to be 
due to the PSA-based screening. The high mortality rates 
observed after implementation of the PSA-based screening 
could be possibly due to the over-reporting of prostate 
cancer as an underlying cause of death in death certificates. 
Similarly, this was noted in the USA in 1991, when many 
men with undetected prevalent cancers were diagnosed 
with prostate cancer and were more likely to have prostate 
cancer assigned as a cause of death when dying.27 In a study 
in Norway, over-reporting of prostate cancer deaths was esti-
mated to be 33%, with significantly higher misattribution 
among older patients, who represent the large majority 
of prostate cancer deaths.28 Misattribution of the cause of 
death in Estonia was one explanation for increasing pros-
tate cancer mortality.16
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ConClusIons
A widespread use of PSA testing seems to be responsible 
for the changes in the epidemiology of prostate cancer in 
north-eastern European countries. Substantial variation 
in the incidence of prostate cancer in the Baltic countries 
likely reflects the use of the PSA test in detecting prostate 
cancer. A lack of effect on prostate cancer mortality was 
observed. Guidelines for the use of the PSA-test as an early 
detection tool, including a joint and informed decision 
process of the physician and the patient, should be devel-
oped and adhered to in all the participating countries. This 
would help to minimise the harm associated with overdiag-
nosis, and to ensure that Belarus, the Russian Federation 
and Ukraine will not experience the marked incidence 
increases seen in the Baltic states.
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